<figure><img alt="" src="https://www.pda.org/images/default-source/default-album/pda-letter/2020/featured-articles/voices-of-the-board.jpg?sfvrsn=87a86f81_6"></img></figure>
It is hard to believe that March 11, 2021 will mark the one-year anniversary when WHO declared COVID-19 a pandemic. In those 12 months, I, like so many of you, have been affected both personally and professionally as we navigate this health crisis together. I have found it difficult to adjust to social distancing, virtual meetings, and my home as an office. I miss seeing the friends at PDA I have made over the years, the professional networking that brought us together to support each other&rsquo;s career development, and the in-person meetings that allowed us to exchange fresh ideas to advance science and technology across the industry.
Yet, when I take a step back and truly reflect on where we are at today, I am inspired by what I see across the industry. There is unprecedented collaboration between companies who are normally competitors and partnership between industry and the regulators to develop and deliver safe and effective vaccines and therapies to patients across the world at a speed that we have not seen previously. Collectively, we have also ensured supply of critical medicines to patients dealing with serious medical conditions. I am proud to be part of this industry and what we are doing to deliver for patients.
I am also proud to be part of PDA during this extraordinary time. I see how PDA over the years has contributed significantly to manufacturing science, technology, and regulations that has allowed industry to rise to this occasion to better serve patients. PDA&rsquo;s extensive library of publications provides pharmaceutical and biopharmaceutical professionals and leaders like me with key advice, guidance, and education on topics like product quality, risk management, and manufacturing practices to ensure the product that we manufacture is safe and efficacious and that we deliver consistently and reliably. I have been fortunate in my career to attend conferences, training, and interest groups sponsored by PDA and each one has been instrumental in strengthening my technical and regulation knowledge and application. I have been taught by the best and I have benefited by those opportunities to engage with my peer group, academia, scientists, and regulators. I think you will find that a PDA membership can be valuable in your career pursuits.
I joined PDA Board of Directors just over a year ago to contribute personally to the advancement of PDA&rsquo;s mission and to give back to an organization that has been so influential in my career and ongoing education as well has helped my company strengthen our procedures and practices to meet regulatory expectations. It has also provided my company the opportunity to have our scientists and quality professionals share our best practices and scientific knowledge with a broader audience and in the spirit of advancing science and technology so we can all benefit. These experiences have always been professionally enlightening and personally rewarding. I hope that my experience inspires you to become more involved and encourage others at your company to do the same.
As a Board member, I want to share the work we are doing to engage and grow our membership at PDA. Last year we conducted a membership survey that has provided valuable insights into what is working well for you and where we could do better. We are taking that information seriously and developing actions to address those opportunities you shared with us. For example, we will be advancing mentorship programs and increasing volunteer opportunities so that we can engage a diverse group of volunteers while ensuring a valuable experience for them. Additionally, PDA will continue to maintain our core competencies in manufacturing, GMP, and quality, by working with current subject-matter experts to identify and develop &ldquo;up and coming&rdquo; experts that will carry the torch into the future. This is a great way to get involved early in your career to build your reputation as an industry expert and leader. Or, you may have a staff member at your company that could benefit from an opportunity like this while also ensuring your company has the latest information and thinking on a specific topic available to them.
Additionally, we heard that you would like us to consider more progressive membership options to deal with the realities of today&rsquo;s business environment and different needs of potential members. I am pleased to share with you that we have developed new membership tiers and PDA entry pathways to make PDA&rsquo;s knowledge and network base more widely accessible globally. Look for information on these options and programs in the very near future.
Finally, developing future experts and leaders is front and center for PDA. We consider this an important aspect of carrying out our vision and mission as an organization. To do this, we are eager to increase our engagement with early career professionals. We want to play an important part in providing learning and development opportunities for these individuals. We have developed targeted programs, networking events, and volunteer opportunities for those early in their career so that they have an opportunity to learn from the network of experts associated with PDA to deepen their technical and regulatory knowledge allowing them to contribute on a larger scale at their company and within the industry. Please check out PDA&rsquo;s website for more information on early career opportunities.
I want to thank our current members for their continued support of PDA, even during the unusual times of this pandemic. This support and sponsorship are important to advancing science and connecting people in our industry. Your feedback is important and is serving as a catalyst for positive change. We continue to evolve our programs, outreach, and volunteer opportunities to meet the needs of our members. I would also like to take this opportunity to invite you to spread the word about PDA and what our global organization has to offer. The value of membership and participation is enhanced for all of us when we have a diverse group of volunteer scientists and experts to shape the practices and standards for the industry.

COVID-19

personal digital assistant

It is hard to believe that March 11, 2021 will mark the one-year anniversary when WHO declared COVID-19 a pandemic. In those 12 months, I, like so many of you, have been affected both personally and professionally as we navigate this health crisis together. I have found it difficult to adjust to social distancing, virtual meetings, and my home as a

The Value of Membership

Search by
BioLaurus
Company Headquarters
2305 Historic Decatur Road , Suite 100, San Diego, CA, 92106, US
Driving Directions Phone: View Phone
View website
Request more information from BioLaurus
Request more information from BioLaurus
Please select Job Function NoneResearch & DevelopmentQuality Assurance/Control ValidationBusiness DevelopmentContr

Categories from BioLaurus

A client in Ireland acquired an aseptic operations facility with plans to expand into GMP microbiology laboratory services, despite having previously outsourced all microbiology work and lacking in-house expertise. Eurofins Professional Scientific Services (PSS) addressed this challenge by deploying a dedicated team of 13 employees working in three

Set Up And Qualify GMP Laboratories

In this interview, Steven Facer, Senior Vice President of Global Sales and Marketing at Adare Pharma Solutions, outlines the essential elements of successful CDMO partnerships in today’s fast-paced, complex pharmaceutical environment. With shrinking timelines and rising development challenges, sponsors increasingly rely on CDMOs that offer deep ora

The Secrets Of A Successful CDMO Partnership

Take the time to understand what you have in place and what you need to do to improve. Without a complete and comprehensive understanding of the current processes, it’s incredibly difficult to make sure that you don’t end up in a worse situation than where you started. This is especially true when you’re working with an array of different processes

Operational Resilience:

The European Medicines Agency (EMA) and the Heads of Medicines Agencies (HMA) have issued recommendations through the Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG) for securing the supply of anti-D immunoglobulins used to prevent RhD immunization during pregnancy in the European Union. The supply is in trouble becaus

EMA Moves to Secure Supply of Critical Drugs Used During Pregnancy

This week's episode is one from the road, recorded in front of a live audience in Boston's Seaport neighborhood during the BIO conference (special thanks to MasterControl for making it happen). Amber Salzman, Ph.D., CEO of Epicrispr Biotechnologies (aka 'Epic Bio') explains how epigenetic editing is revolutionizing genetic medicine by controlling g

BoB Live At BIO: Amber Salzman, Ph.D., Epicrispr Biotechnologies

Arcus Biosciences announced that quemliclustat, an investigational small-molecule CD73 inhibitor, was granted orphan drug designation by the U.S. Food and Drug Administration to treat pancreatic cancer.
Orphan drug designation is intended to support the development and evaluation of new treatments for rare diseases affecting fewer than 200,000 peop

Arcus' Quemliclustat Receives Orphan Drug Designation

Joachim Kreuzburg, the long-time former CEO of leading biotechnology firm Sartorius, has reemerged at Cube Biotech, where he has joined the board of directors.
The appointment has injected a shot of star power into the German biotech firm, which serves as a supplier much like Kreuzburg’s former company. But unlike his former company, Cube Biotech i

Former Sartorius boss leads class of biotech executive shakeups

By Laura Walls, PhD, Technical Project Leader, and Sharyn Farnsworth, MSc, Director of Upstream Development
The use of Baculovirus expression vector systems (BEVS) in insect cells is a highly efficient and scalable method for producing biologics. This technology is particularly effective in producing high concentrations of multi-protein subunit com

The Perfect Hosts For Vaccine And Virus Expression: Insect Cell Expression Systems

Thursday, July 10, 2025
IASO Biotherapeutics a biopharmaceutical company focused on the discovery, development, manufacturing, and commercialization of innovative cell therapies and biologics, today announced that its self-developed anti-BCMA CAR-T cell therapy product, Equecabtagene Autoleucel (Fucaso), has been granted Orphan Drug Designation (OD

IASO Bio Receives Orphan Drug Designation from the Ministry of Food and Drug Safety of South Korea for Equecabtagene Autoleucel

Medical Device Recalls
VersaCross RF Wire (VXW). Indicated for creation of an atrial septal defect in the heart. Product...
2
07/10/2025
Boston Scientific Corporation
Bravo CF capsule delivery device, designed to place and attach a pH monitoring capsule to the esopha...
1
07/10/2025
Given Imaging Ltd.
BiPAP A40 Ventilator. Used to provide noninvasi

Medical Device Recalls

Application for Single Medicine Product
A single medicine product is a medicine that consists of one single medicine unit.
Client Reference
The Client Reference field is the Sponsor's or Agent's own internal reference information. This reference information is not visible to TGA when the application is submitted.
Applicant Details
Applicant Name
Th

PM - Application for Single Medicine Product

Complete Response Letters On-Line – Never Thought It Would Happen!
I opened my browser this morning at 6AM PST and the first thing I saw was an FDA notice I never thought I would see. Right there on my computer, the Notice (here) said “FDA Embraces Radical Transparency by Publishing Complete Response Letters”. Yes, that’s right – CRLs are now being

Complete Response Letters On-Line – Never Thought It Would Happen!

US pharma major AbbVie (NYSE: ABBV) and IGI Therapeutics SA, a wholly owned subsidiary of New York-based Ichnos Glenmark Innovation today announced an exclusive licensing agreement for IGI's lead investigational asset, ISB 2001, developed using IGI's proprietary BEAT protein platform, for oncology and autoimmune diseases.
The deal is potentially wo

AbbVie and Ichnos Glenmark ink antibody license deal

Gilead Sciences Inc. has partnered with the Global Fund to Fight AIDS, Tuberculosis and Malaria (Global Fund) to supply lenacapavir—Gilead’s twice-yearly injectable HIV-1 capsid inhibitor—for the prevention of HIV as pre-exposure prophylaxis (PrEP).
Through the agreement, Gilead will supply enough doses to reach up to two million people over three

Gilead & Global Fund Partner for HIV Prevention

Thursday, July 10, 2025
Sartorius Stedim Biotech has entered into a Memorandum of Understanding (MoU) with Sensible Biotechnologies to support the scale-up and industrialisation of Sensible’s cell-based mRNA design and manufacturing platform.
The collaboration aims to enable the clinical-grade production of cell-based mRNA by 2026. It is expected t

Sartorius Stedim Biotech and Sensible Biotechnologies to Scale Up Cell-Based mRNA Manufacturing Platform

French biotech Osivax has published results from a Phase IIa trial showing that its lead candidate OVX836, a broad-spectrum influenza vaccine, demonstrated a strong safety profile and immune response when administered alongside a conventional flu shot.
The findings, now available in the journal Vaccines, stem from a 180-person study evaluating the

Osivax reports positive mid-stage data for flu vaccine candidate OVX836

Emmanuel Cansino (Senior Director Industry Solutions) will present the webinar Why is Manual Validation Holding you Back? The Evolution of AI-Driven Validation in Regulated Industries on Aug 6, at 8:00 AM EDT. There is a second session at 12:00 PM EDT.
Manual validation, while thorough, often leads to delays, human errors, and compliance headaches.

Why is Manual Validation Holding you Back? The Evolution of AI-Driven Validation in Regulated Industries

Proteros biostructures GmbH, an early-stage drug discovery services provider in Germany, has announced an agreement with Qanatpharma of Switzerland, Zuse Institute Berlin (ZIB), and Ukraine-based Enamine to launch a research collaboration intending to leverage innovations from all four partners—notably, ZIB’s artificial intelligence (AI)-based gene

Generative AI-Driven Collaboration to Research Treatments for Brain Hemorrhage Complications

Aptar CSP Technologies, part of AptarGroup, Inc. and a leader in active material science, has developed a dual-active material science technology engineered to simultaneously control moisture and oxygen. This technology is designed to provide a singular solution to address these degradation drivers for pharmaceutical drugs, including oral solid dos

Aptar Develops Moisture and Oxygen Controlling Technology

I return you to five minutes before Donald Trump officially became president on January 20th, and to a time when the FDA was near perfect.
That’s what one would assume today listening to the many of us up in arms over the agency.
Of course, the reality was quite different. We seem to have erased the memory that segments of our biopharma industry –

The FDA Was Darned Near Perfect, Right?

Getty images. Credit: Tom Werner
Some 75% majority of Americans struggle to take their medications as directed, according to the National Library of Medicine (NLM). This widespread problem—known as medication nonadherence—can make medications ineffective leading to significant worsening of disease, increased medical costs, or death. There are 125,0

New Packaging Breakthrough Reduces Medication Nonadherence

Wednesday, July 09, 2025
Veeda Lifesciences, a global contract research organization (CRO), has announced an investment in Mango Sciences, a Boston-based healthcare AI and data company. Through this investment, Veeda intends to leverage AI capabilities to enhance the speed, efficiency, and quality of Clinical Trials services across its expanded glo

Veeda Lifesciences announces partnership with Mango Sciences to bring AI innovation in clinical trials services

An official website of the European Union
en
Public Health
Home
Publications
Report on the implementation of the EU Global Health Strategy
Background document
Report on the implementation of the EU Global Health Strategy
Page contents
Details
Files
Details
Publication date
Author
Directorate-General for Health and Food Safety
Files
10 JULY 2025
int

Report on the implementation of the EU Global Health Strategy

Search Query: root_codes_comments:"Dopamine receptor antagonist"
Browse Substances
Newest Change
Sort By
Search Within Results
Items per page:
10
1 – 1 of 1
Page:
of 1
METOCLOPRAMIDE
L4YEB44I46
ACHIRAL
Names:
Loading
Relationships:
25
Mol. Weight:
299.8
Formula:
C14H22ClN3O2
Substance Hierarchy
Loading
Items per page:
10
1 – 1 of 1
Page:
of 1

Browse Substances

Advertise in the PDA News uPDAte & Buyer’s Guide

Contact

Advertise

Other industries

With the increased expectation to adopt modern microbial methods, more technology users are being tasked with evaluating and developing implementation strategies for advanced methods.
There is a desire to couple regulatory guidelines with industry expertise to develop standardized tools that make implementation a less daunting task and one that is